BioNTech's Pipeline Math: A Colorectal Setback, a Seoul Survival Win, and the Long Wait to 2028

BioNTech's mRNA colorectal vaccine was shelved in September, but gotistobart nearly doubled survival in lung cancer as BMO downgraded the stock.

BioNTech spent September proving a point that few biotech investors enjoy hearing: a pipeline built on multiple simultaneous cancer bets will deliver triumph and disappointment in the same news cycle. The German company's mRNA colorectal cancer vaccine was shelved early in the month after an independent committee concluded the treatment offered no survival benefit. Reuters reported that US-listed shares fell 7.5% on the news. Yet by the close of the following session the stock sat at EUR 83.75 — just 0.5% below its 50-day moving average of EUR 84.17. That muted reaction says as much about how the market now frames BioNTech as any clinical data point could.

Seoul Delivers the Counterweight

Days later, at the IASLC World Conference on Lung Cancer in Seoul, BioNTech and partner OncoC4 presented updated Phase 3 data for gotistobart showing the antibody nearly doubled median overall survival in previously treated squamous non-small cell lung cancer compared with standard chemotherapy. The same conference brought the first global data on a combination of pumitamig and elfetabart drozuntecan. For a company whose oncology pipeline increasingly dictates its valuation — while the Comirnaty vaccine franchise fades — the double presentation was a timely reminder of what the broader portfolio can do.

The contrast is the story. One front retreats, another advances, and anyone judging BioNTech on a single day's headline will be whipsawed indefinitely.

BMO Steps Back From the Bull Case

Not everyone read the Seoul data as a turning point. On 8 September, BMO Capital Markets downgraded the stock from Outperform to Market Perform and cut its price target to USD 105. The brokerage cited a faster-than-expected erosion of the Comirnaty business, an absence of de-risking data for pumitamig until 2028, and tempered expectations for the mRNA program iNeST. Since then the shares have traded in a narrow band just above EUR 84 — a market waiting for confirmation rather than picking a direction.

The COVID franchise, meanwhile, remains a cash-flow anchor rather than a growth engine. In August the company trimmed its 2026 revenue guidance to EUR 1.6–1.9 billion from EUR 2.0–2.3 billion, blaming weaker vaccine demand. That revision is now more than a month old and appears absorbed into the price — background noise rather than a fresh shock, and largely overshadowed by the oncology narrative.

The Question That Matters

Over the coming months everything funnels into a single issue: can the oncology pipeline — gotistobart above all, plus the pumitamig combination — replace the shrinking Comirnaty business in value terms before the gap BMO identifies becomes a genuine drag ahead of credible pumitamig data in 2028? The survival figures just released are a strong signal, but they are not an approval.

An entry for gotistobart that surfaced in an FDA database confirms only that the program is registered there; it does not indicate a new regulatory decision or a label expansion. The distance between promising trial results and a commercially usable approval remains the crux of the valuation.

Where the Upside Lives

Should the PRESERVE-003 results hold up in further analyses and the program move swiftly toward a regulatory filing, gotistobart could become BioNTech's first major commercial oncology product. Nearly doubled survival versus chemotherapy, in an indication with limited options, would be a differentiating advantage. The newly unveiled pumitamig combination data add optionality on top: solid response rates there would underscore the pipeline breadth that even BMO's more skeptical stance does not dispute. In that scenario the market would likely look past Comirnaty weakness and anchor the valuation more firmly to clinical milestones.

Where the Risk Sits

The danger is timing. BMO explicitly notes that meaningful de-risking data for pumitamig probably will not arrive until 2028 — a long wait during which, by the analysts' reckoning, the Comirnaty business shrinks faster than previously assumed. Positive Phase 3 data are also no substitute for approval: regulatory reviews can drag on, and the FDA entry for gotistobart so far offers no hint of an imminent decision. If vaccine revenue erodes further without the oncology pipeline contributing sales in the foreseeable future, a valuation gap would open that the market would struggle to ignore. The stock's annualized volatility of 72% already reflects that uncertainty.

A Stock Caught Between Two Clocks

Even the most recent trading session made the tension visible: shares gave up 2.2% on the day, unable to hold onto the lung cancer momentum. That may look paradoxical, but it captures a market that has not yet resolved two opposing oncology signals into a clear direction.

As long as BioNTech keeps delivering positive clinical readouts like the ones from Seoul and the share price stabilizes near its 200-day moving average — as it currently does — the picture stays balanced, with neither a clear upward trend nor a sustained decline. Should sentiment tilt toward accelerating Comirnaty weakness without regulatory progress on gotistobart or the pumitamig combination, the valuation gap BMO sketches would move to the foreground.

The next concrete test is whether, and when, the Seoul data become a formal marketing application. Until then, the stock remains wedged between pipeline hope and revenue worry — and investors should brace for more turns, because certainty is the one thing this pipeline is not offering.